期刊文献+

晚期结直肠癌靶向治疗进展与出路探讨 被引量:2

Progress and solution in targeted therapy of advanced colorectal cancer
暂未订购
导出
摘要 对结直肠癌中关键信号通路的认识有助于在靶向治疗中确定特异的分子标志物。本综述基于此点进行论述,揭示BRAF、NRAS等多个有潜力的生物学标志在结直肠癌治疗中的地位及意义,系统介绍目前治疗结直肠癌的靶向药物,寻求真正有价值的分子靶标在结直肠癌靶向治疗中的应用价值。 The knowledge about key signaling pathways in colorectal tumors has contributed to the identification of specific molecular markers of response to targeted agents.In this review we discuss well-established and potential predictive biomarkers including BRAF,NRAS,and PI3KCA mutations,and PTEN loss are also reviewed personalized cancer medicine in the mCRC scenario seems to be near reality,but many biomarkers in prospective clinical trials is urgently to be validated.
出处 《现代肿瘤医学》 CAS 2013年第11期2589-2593,共5页 Journal of Modern Oncology
基金 国家自然科学基金(编号:81172094)
关键词 结直肠癌 靶向治疗 表皮生长因子受体信号通路 colorectal cancer individual treatment targeted therapy EGFR signal pathway
  • 相关文献

参考文献27

  • 1Ciardiello F, Tortora G. EGFR antagonists in cancer treatment [ J ]. N Engl Med,2008,358:1160 - 1174.
  • 2Scaltriti M, Baselga J. The epidermal growth factor receptor path- way:a model for targeted therapy[J]. Clin Cancer Res,2006,12: 5268 - 5272.
  • 3Shepard HM, Brdlik CM, Schreiber H. Signal integration : a frame- work for understanding the efficacy of therapeutics targeting the hu- man EGFR family[ J ]. J Clin Invest,2008,118:3574 - 3581.
  • 4Ciardiello F, Tortora G. EGFR antagonists in cancer treatment [ J ]. N Engl J Med ,2008,358.1160 - 1174.
  • 5Rodriguez - Viciana P, Warne PH, Dhand R, et al. Phosphatidyli- nositol - 3 - OH kinase as a direct target of Ras[ J]. Nature, 1994, 370:527 - 532.
  • 6Malumbres M, Barbacid M. RAS oncognnes : the first 30 years. Tar- geting RAS signalling pathways in cancer therapy [ J ]. Nat Rev Cancer,2003,3 : 11 - 22.
  • 7Downward J. Targeting RAS signalling pathways in cancer therapy [ J]. Nat Rev Cancer,2003,3 : 11 - 22.
  • 8De Roock W, Claes B,Bernasconi D,et al. Effects of KRAS, BRAF, NRAS,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy - refractory metastatic colorectal cancer: a retrospective consortium analysis [ J ]. Lancet Oncol, 2010,11:753 - 762.
  • 9Di Nicolantonio F, Martini M, Molinari F, et al. BRAF wild - type is required for response to panitumumab or cetuximab in metastat- ic colorectal cancer[ J]. Clin Onco1,2008 ,26 :5705 - 5712.
  • 10Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite - stable colon cancers [ J ]. Cancer Res,2005,65:6063 - 6069.

同被引文献6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部